Monday, May 2, 2016

BRIEF-Tobira provides interim 12-week results from ORION study

* Cenicriviroc treatment was observed to be safe and

well-tolerated with adverse events being comparable to placebo

Read more
Posted by at

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)